CALCA and medullary thyroid gland carcinoma: Data from the cardiovascular outcome trials suggested that 3-year exposure to GLP-1RAs did not affect the calcitonin level nor increase the risk of new diagnoses of medullary thyroid carcinomas (34, 35, 36, 37).